We previously showed that newborn piglets who develop pulmonary hypertension during exposure to chronic hypoxia have diminished pulmonary vascular NO production and evidence of eNOS uncoupling. Tetrahydrobiopterin (BH4) is a co-factor that promotes eNOS coupling. Current clinical strategies typically invoke initiating treatment after the diagnosis of pulmonary hypertension, rather than prophylactically. The major purpose of this study was to determine whether starting treatment with an oral BH4 compound, Sapropterin Dihydrochloride (Sapropterin), after the onset of pulmonary hypertension would re-couple eNOS in the pulmonary vasculature and ameliorate disease progression in chronically hypoxic piglets. Normoxic (control) and hypoxic piglets were studied. Some hypoxic piglets received oral Sapropterin starting on day 3 of hypoxia and continued throughout an additional 7 days hypoxic exposure. Catheters were placed for hemodynamic measurements and pulmonary arteries were dissected to assess eNOS dimer-to-monomer ratios (a measure of eNOS coupling), NO production, and superoxide (O2•-) generation. Although higher than in normoxic controls, pulmonary vascular resistance was lower in Sapropterin-treated hypoxic piglets than in untreated hypoxic piglets. Consistent with eNOS re-coupling, eNOS dimer-to-monomer ratios and NO production were greater and O2•- generation was less in pulmonary arteries from Sapropterin-treated than untreated hypoxic animals. When started after disease onset, oral Sapropterin treatment inhibits chronic hypoxia-induced pulmonary hypertension at least in part by recoupling eNOS in the pulmonary vasculature of newborn piglets. Rescue treatment with Sapropterin may be an effective strategy to inhibit further development of pulmonary hypertension in newborn infants suffering from chronic cardiopulmonary conditions associated with episodes of prolonged hypoxia.